HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells by unknown
Frank et al. Epigenetics & Chromatin  (2016) 9:15 
DOI 10.1186/s13072-016-0065-5
RESEARCH
HDAC inhibitors cause site-specific 
chromatin remodeling at PU.1-bound  
enhancers in K562 cells
Christopher L. Frank1,2, Dinesh Manandhar2,3, Raluca Gordân2,4 and Gregory E. Crawford2,5*
Abstract 
Background: Small molecule inhibitors of histone deacetylases (HDACi) hold promise as anticancer agents for 
particular malignancies. However, clinical use is often confounded by toxicity, perhaps due to indiscriminate hypera-
cetylation of cellular proteins. Therefore, elucidating the mechanisms by which HDACi trigger differentiation, cell cycle 
arrest, or apoptosis of cancer cells could inform development of more targeted therapies. We used the myelogenous 
leukemia line K562 as a model of HDACi-induced differentiation to investigate chromatin accessibility (DNase-seq) 
and expression (RNA-seq) changes associated with this process.
Results: We identified several thousand specific regulatory elements [~10 % of total DNase I-hypersensitive (DHS) 
sites] that become significantly more or less accessible with sodium butyrate or suberanilohydroxamic acid treat-
ment. Most of the differential DHS sites display hallmarks of enhancers, including being enriched for non-promoter 
regions, associating with nearby gene expression changes, and increasing luciferase reporter expression in K562 cells. 
Differential DHS sites were enriched for key hematopoietic lineage transcription factor motifs, including SPI1 (PU.1), 
a known pioneer factor. We found PU.1 increases binding at opened DHS sites with HDACi treatment by ChIP-seq, 
but PU.1 knockdown by shRNA fails to block the chromatin accessibility and expression changes. A machine-learning 
approach indicates H3K27me3 initially marks PU.1-bound sites that open with HDACi treatment, suggesting these 
sites are epigenetically poised.
Conclusions: We find HDACi treatment of K562 cells results in site-specific chromatin remodeling at epigenetically 
poised regulatory elements. PU.1 shows evidence of a pioneer role in this process by marking poised enhancers but is 
not required for transcriptional activation.
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Background
Large cancer genotyping efforts such as The Cancer 
Genome Atlas (TCGA) have found epigenetic regula-
tors are frequent targets of oncogenic mutation and 
translocation. For instance, 76  % of urothelial carcino-
mas analyzed by TCGA were found to carry at least one 
inactivating mutation in a chromatin regulatory gene [1]. 
These types of mutations are thought to lead to aberrant 
epigenetic states at many loci in the genome that together 
contribute to expression patterns and signaling cascades 
that facilitate oncogenic phenotypes. Alongside these 
discoveries, chromatin regulator-targeted pharmacologi-
cal therapies have shown the potential to reverse aber-
rant epigenetic states driving cancer cell proliferation [2]. 
Histone deacetylase inhibitors (HDACi) represent one 
class of compounds with this potential.
The majority of HDACi investigated for anticancer 
application act to block removal of acetyl groups from 
protein lysines by inhibiting the active sites of zinc-
dependent class I, II, and IV histone deacetylases [3, 
4]. HDACi are capable of inducing cell cycle arrest, dif-
ferentiation, and apoptosis in a variety of preclinical 
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cancer models, and thus far three HDACi have been FDA 
cleared for anticancer applications [3, 4]. In clinical trials, 
multiple HDACi have been shown to have severe dose-
limiting toxicities [5], indicating that a more nuanced 
understanding of HDACi anticancer effects could be 
beneficial to the development of more specific and well-
tolerated therapies.
Exposure to HDACi is thought to increase chromatin 
acetylation levels genome wide [6, 7] but in many cases 
the exact mechanisms by which HDACi stop cancer cell 
proliferation remain poorly defined. Increased histone 
tail acetylation levels have classically been associated with 
relaxation of local chromatin and greater accessibility for 
transcription factor binding [3, 8]; however, more recent 
studies show that specific histone acetylation marks 
demarcate different gene regulatory element functions 
and are dynamically maintained and read by trans-acting 
“writer,” “eraser,” and “reader” factors [9, 10]. Further-
more, previous studies report only a fraction (~10  %) 
of genes respond to HDACi treatment with expression 
changes, indicating these compounds are more specific 
than would be expected by global histone hyperacetyla-
tion [11, 12]. Therefore, a better understanding of how 
these drugs impact gene expression is necessary.
The ability of HDACi to induce differentiation 
responses analogous to the highly effective all-trans reti-
noic acid therapy used in acute promyelocytic leukemia 
[13] is a particularly interesting application of these com-
pounds that could be useful for resensitizing cancer cells 
to other chemotherapeutics or eliminating cancer stem 
cells. For over 30  years, it has been noted that HDACi 
treatment of the myelogenous leukemia line K562 results 
in differentiation along an erythrocytic lineage [14, 15], 
providing a well-characterized system for HDACi-initi-
ated differentiation.
To investigate the relationship between chromatin 
changes and the transcriptional response to HDACi 
treatment in the context of induced cancer cell differ-
entiation, we measured genome-wide chromatin acces-
sibility (DNase-seq) and expression (RNA-seq) changes 
resulting from sublethal HDACi treatment of K562 cells. 
As cell proliferation slowed, we detected several thou-
sand gene regulatory elements where chromatin acces-
sibility increased or decreased. These changes coincide 
with nearby gene expression changes and likely repre-
sent enhancer element activation or deactivation events. 
Motif enrichment analysis indicated that the pioneer fac-
tor PU.1 was bound to many of the newly opened DHS 
sites, which we confirmed by ChIP-seq. Since PU.1 is 
known to be involved in hematopoietic cell differen-
tiation [16, 17], we tested whether overexpression and 
knockdown of PU.1 could explain the HDACi observed 
changes in chromatin and expression. Overexpression of 
PU.1 modestly opened the DHS sites shown to be opened 
by HDACi treatment, and shRNA-mediated knockdown 
of PU.1 failed to block the chromatin accessibility and 
gene expression changes associated with HDACi treat-
ment. Together, this suggests that while PU.1 is present 
at sites of HDACi-induced chromatin changes, this fac-
tor is not the primary driver of these changes. Instead, a 
machine-learning approach suggests that enrichment of 
H3K27me3 specifically marks HDACi-responsive DHS 
sites. These findings add to our mechanistic knowledge 
of how HDACi alter chromatin and gene expression pat-
terns, induce differentiation, and ultimately block cancer 
cell proliferation.
Results
HDACi drive site‑specific chromatin accessibility changes 
in K562 cells
To assess the extent of chromatin accessibility changes 
cancer cells might undergo as a result of HDACi treat-
ment, we performed DNase-seq on the myelogenous 
leukemia line K562 following 72-h incubations with the 
0.5 mM sodium butyrate (NaBut) or 1 μM suberanilohy-
droxamic acid (SAHA). These concentrations were cho-
sen as high enough to slow K562 proliferation by ~50 % 
but limit cell death at 72 h to less than 10 %. DESeq2 [18] 
was used to quantitatively compare DNase signal from 
vehicle control to treated cells (Fig.  1a, b; Additional 
file 1: Table S1). Our analysis found roughly equal num-
bers of DHS sites that significantly “open” and “close” in 
response to treatment: NaBut treatment resulted in 1151 
opening DHS sites and 1132 closing DHS sites, while 
SAHA resulted in 7962 opening DHS sites and 10,349 
closing (FDR  <  0.05). We note that many of these DHS 
sites display remarkably specific accessibility changes 
amongst surrounding DHS sites that do not change 
(Fig.  1c, d). The majority of the HDACi-opened and 
HDACi-closed DHS sites are located outside of proxi-
mal promoter regions (Fig. 1e), suggesting these elements 
may be distal enhancers.
Although the two drug treatments resulted in approxi-
mately tenfold different totals of differential DHS sites, 
we found the direction of signal changes was remark-
ably similar between drugs across these sites (Additional 
file  2: Fig. S1A–D). Additionally, increasing NaBut con-
centration fourfold to 2  mM over the same 72-h treat-
ment resulted in a 15,599 additional differential DHS 
sites at FDR < 0.05 (Additional file 2: Fig. S1E). This sug-
gests the two HDACi are capable of inducing similar 
chromatin accessibility changes and that the differences 
in the number of differential DNase sites are likely due to 
inhibitor potency. Indeed, a principle components anal-
ysis separates vehicle controls from both drug-treated 
populations along the first principal component (Fig. 1f ), 
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implying the greatest source of variation in these data is 
an HDACi response in common to NaBut and SAHA. 
Clustering samples by Euclidean distance between regu-
larized log-transformed DHS signal (Additional file  2: 
Fig. S1F) further supports the notion these two drug 
treatments result in similar global chromatin accessibility 
changes in K562 cells.
HDACi‑opened and HDACi‑closed DHS sites associate 
with directional gene expression changes
RNA-seq was used to investigate the relationship 
between the HDACi-induced chromatin accessibility 
changes and transcriptional regulation. Using a FDR of 
0.05, we identified 1464 differentially expressed genes 
with NaBut treatment and 6808 differentially expressed 
genes in the SAHA treatment (Additional file  3: Table 
S2). A high degree of overlap was observed between 
treatments with the two HDACi compounds (Fig.  2a, 
b). Associating each DHS site with its nearest gene 
and plotting the cumulative fraction of genes that dis-
play an increasing fold-change of expression level from 
vehicle to HDACi treatment revealed a strong associa-
tion between locally opening DHS sites and increased 
gene expression for both HDACi (Mann–Whitney test, 
P = 3.3 × 10−54 for NaBut, P = 1.8 × 10−54 for SAHA) 
(Fig.  2c, d). A weaker, but still statistically significant 
association was observed between closing DHS sites 
and decreased nearby gene expression (Mann–Whit-
ney test, P = 4.7 × 10−13 for NaBut, P = 2.2 × 10−10 for 
SAHA). These effects were stronger when considering 
only those genes that were associated with two or more 
direction-matched DHS site changes, indicating that 
these sites have an additive effect on expression (Fig. 2c, 
d). Together, these results show DHS site opening often 
marks increases in local transcription levels and support 
that opened DHS sites are enhancers. Similarly, closing 
DHS sites may represent reduced distal enhancer activity.
To further test whether HDACi-opened DHS sites 
function as enhancers in K562 cells, we cloned eight 
~800-bp regions encompassing HDACi-opened DHS 
sites in front of a minimal promoter driving luciferase 
reporter expression. At 24  h post-transfection into 
K562 cells, we treated cells with NaBut, SAHA, or their 
respective vehicle controls for 24  h and then measured 
luciferase activity. Normalizing signal to co-transfected 
Renilla luciferase, we detected luciferase activity elevated 
above the minimal promoter construct alone for five 
of the eight elements in untreated K562 cells (Fig.  2e, 
f ). Importantly, the addition of either NaBut or SAHA 
resulted in seven of the eight elements significantly 
increasing luciferase activity. This effect was not observed 
in a known strong enhancer that does not increase in 
accessibility following HDACi treatment (Fig.  2e, f ). 
Together, these results suggest many opened DHS sites 
indeed function as enhancer elements and that these ele-
ments become more active upon HDACi treatment.
PU.1 binds preferentially at opened DHS sites
Motif enrichment analysis of DHS sites that open follow-
ing NaBut or SAHA treatment revealed an ETS family 
binding motif that closely matched the position weight 
matrix for SPI1 (PU.1) and was unique to HDACi-opened 
DHS sites (Fig.  3a; Additional file  4: Fig. S2). Although 
the large family of ETS transcription factors have highly 
similar DNA-binding motifs [19], we found PU.1 was the 
only ETS factor with a significant increase in expression 
level following both NaBut and SAHA treatments in our 
RNA-seq data (Additional file 5: Table S3). PU.1 has also 
been described as a pioneer factor in macrophage and B 
lymphocyte differentiation with the ability to establish 
cell lineage-specific enhancer elements by binding and 
recruiting cofactors and chromatin remodeling proteins 
[16, 17]. We therefore hypothesized PU.1 may play a sim-
ilar role in establishing functional enhancer elements in 
K562 cells at newly opened DHS sites following HDACi 
treatment.
We first tested PU.1 binding by chromatin immuno-
precipitation qPCR (ChIP-qPCR) at six DHS sites that 
both open with HDACi treatment and contain at least 
one canonical 5′-GGAA-3′ PU.1-binding motif. Enrich-
ment of PU.1 occupancy was detected for each of the six 
tested sites (Additional file 6: Fig. S3A, B), and substan-
tial increases in PU.1 occupancy were observed following 
either SAHA (Fig. 3b) or NaBut (Fig. 3c) 72-h treatments. 
PU.1 binding and establishment of functional enhancers 
has been previously reported to coincide with increased 
(See figure on previous page.) 
Fig. 1 HDACi treatment induces site-specific chromatin remodeling in K562 cells. a MA plot of fold-change in K562 chromatin accessibility (DNase-
seq signal) over average signal found at each site following 72-h 0.5 mM NaBut treatment. Red marks DHS sites with significantly changed chro-
matin accessibility (FDR < 0.05, n = 3 replicates). b MA plot of fold-change in K562 chromatin accessibility over average signal following 72-h 1 μM 
SAHA treatment. Red marks DHS sites with significantly changed chromatin accessibility (FDR < 0.05, n = 3 replicates). c Representative example of 
SAHA-opened DHS site found near the promoter of CD207. d Representative example of SAHA-closed DHS site found in an intron of DNMT3A. e Dis-
tribution of all DHS sites and differential DHS sites between promoter (< 2 kb from TSS) and non-promoter location. f Regularized log-transformed 
DNase-seq data for vehicle control K562 (DMSO or PBS) and HDACi-treated K562 (0.5 mM NaBut, 2 mM NaBut, or 1 μM SAHA) plotted in first two 
principal components of PCA
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Fig. 2 Chromatin accessibility changes are associated with transcriptional changes from HDACi treatment. Overlap between sets of up (a)- or 
down (b)-regulated genes (FDR < 0.05) following 72-h NaBut (n = 3 replicates) or SAHA treatment (n = 2 replicates) of K562 cells. Association of 
chromatin accessibility changes with nearby changes in gene expression resulting from NaBut (c) or SAHA (d) treatment. Plots show the cumula-
tive fraction of genes exhibiting that level of fold-change in expression on the x-axis. Sets of all expressed genes, genes closest to an opened DHS 
site, genes closest to a closed DHS site, genes closest to 2 or more opened DHS sites, and genes closest to 2 or more closed DHS sites are plotted. 
Mann–Whitney test used to assess significance between gene sets and all expressed genes. e, f Luciferase assay results for eight DHS sites cloned 
in front of a minimal promoter (pGL4.23) that open following HDACi treatment, and a known strong enhancer (SE) control. Data points show 12–18 
replicates per construct with mean and standard deviation in black. Blue points mark level of normalized luciferase activity in K562 cells with vehicle 
control (1× PBS or DMSO) added and points in red show level of normalized luciferase activity with 1 mM NaBut or 1 μM SAHA added for 24 h. Note 
y-axis is on log scale. Asterisk (*) denotes significant by Bonferroni-corrected two-sided T test (P = 2.8 × 10−13, 2.4 × 10−15, 3.6 × 10−7, 1.6 × 10−10, 
4.5 × 10−12, 0.17, 1.8 × 10−12, and 3.5 × 10−5 from left to right for NaBut; P = 8.1 × 10−8, 5.0 × 10−6, 2.2 × 10−4, 0.0016, 3.0 × 10−7, 0.65, 3.7 × 10−4, 
and 0.0040 from left to right for SAHA)
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local deposition of the histone enhancer mark H3K4me1 
[16]. We detected H3K4me1 enrichment at each of the 
six sites prior to HDACi treatment (Additional file  6: 
Fig. S3C) that modestly decreased at five of the six sites 
following treatment (Fig. 3d), possibly reflecting nucleo-
some repositioning.
To characterize genome-wide PU.1-binding changes 
with HDACi treatment, ChIP-seq was performed on 
vehicle and SAHA-treated K562 cells in triplicate, which 
identified 31977 PU.1-binding sites in total. We observed 
hundreds of sites with increased PU.1 binding following 
HDACi treatment similar to those flanking the CDKN1A 
gene (p21) (Fig. 3e), a well-studied tumor suppressor that 
mediates p53-dependent G1 growth arrest and becomes 
up-regulated following HDACi treatment [20]. As pre-
dicted, PU.1 binding was highly enriched in opened DHS 
sites relative to all DHS sites in K562 cells or closed DHS 
sites (Fig. 3f). Interestingly, PU.1 ChIP-seq signal increased 
globally at the vast majority of peaks following SAHA 
treatment (Fig. 3g) while maintaining a similar distribution 
of total binding sites. This result was detected in each of 
the three replicates processed as pairs of HDACi-treated 
and vehicle control cells. The global increase in PU.1 bind-
ing also matches our ChIP-qPCR results (Fig. 3b, c).
PU.1 overexpression modestly increases accessibility
In addition to our ChIP-seq showing global increases 
in PU.1 occupancy following SAHA treatment, we 
also detected that PU.1 expression levels increase dur-
ing HDACi exposure in our RNA-seq data (Additional 
file  7: Fig. S4A). PU.1 transcription is known to be 
tightly regulated during normal hematopoietic differ-
entiation with different expression levels facilitating key 
transition points in cell lineage [21, 22]. To test whether 
HDACi-induced up-regulation of PU.1 was responsible 
for the chromatin accessibility changes, we transfected 
K562 cells with either a PU.1 cDNA under control of a 
viral promoter or an empty vector control. We selected 
for transformed cells by G418 resistance and performed 
DNase-seq. On the day of cell harvest, we confirmed 
PU.1 overexpression by qPCR (Additional file 7: Fig. S4B) 
and western blot (Fig. 4a).
To characterize the impact of overexpression of PU.1 
on chromatin accessibility, we analyzed the original 
set of 7962 SAHA-opened DHS sites and divided them 
by those bound by PU.1 (n =  2137) versus the remain-
ing that did not bind PU.1 (n = 5825). For the 2137 sites 
bound by PU.1, we observed a reproducible increase in 
mean accessibility in cells that overexpress PU.1 (Fig. 4b). 
This increase in accessibility was not detected at the 5825 
SAHA-opened DHS sites that do not bind PU.1 (Fig. 4b). 
Furthermore, the distribution of fold-changes in acces-
sibility found at SAHA-opened DHS sites with PU.1 
binding was significantly greater than that of the SAHA-
opened DHS sites without PU.1 binding (Mann–Whitney 
test, P < 2.9 × 10−59) or PU.1-bound DHS sites that did 
not open further with SAHA treatment (P < 6.7 × 10−39) 
(Fig. 4c). These patterns are exemplified by two DHS sites 
found in the same intron of the TMEM51 gene; both sites 
open with SAHA treatment, but only the site with PU.1 
bound displays increased hypersensitivity following PU.1 
overexpression (Fig.  4d). The difference between PU.1-
bound DHS sites that open and those that do not increase 
accessibility with SAHA treatment cannot be explained 
by differing baseline levels of PU.1 binding (Additional 
file  7: Fig. S4C). Together these analyses suggest a sub-
set of PU.1 bound DHS sites become more accessible in 
response to elevated PU.1 expression and that this sub-
set overlaps many of the same DHS sites that open up in 
response to HDACi treatment.
Depletion of PU.1 fails to block HDACi‑induced chromatin 
accessibility and expression changes
To determine whether PU.1 is required for the chroma-
tin accessibility increases observed with HDACi treat-
ments, we reduced PU.1 levels using shRNA knockdown. 
Two shRNA constructs that target PU.1 mRNA and a 
non-hairpin control vector were transfected into K562, 
and stable transformants were selected with puromycin 
(Fig.  5a). After selection, cells were treated with SAHA 
or vehicle control for 72  h and processed for DNase-
seq. Reduced PU.1 expression was confirmed on the day 
of cell harvest by qPCR (Additional file 8: Fig. S5A) and 
western blot (Fig. 5b).
(See figure on previous page.) 
Fig. 3 PU.1 increases binding at HDACi-opened DHS sites. a PU.1 motif enrichment detected in NaBut and SAHA-opened DHS sites with motif 
logo, expected (E) value, and top JASPAR database motif match found. See Additional file 4: Fig. S2 for all top motif enrichments. ChIP-qPCR was per-
formed for six DHS sites that open in K562 cells following HDACi treatment and a control site that does not change accessibility. The fold-change of 
PU.1 pull-down enrichment following SAHA (b) or NaBut (c) 72-h treatment is plotted for each site. Error bars are SEM (n = 3 replicates). d ChIP-qPCR 
for the same six DHS sites for H3K4me1 immunoprecipitation. The fold-change of H3K4me1 pull-down enrichment following 72-h SAHA treatment 
is plotted for each site. Error bars are SEM (n = 3 replicates). e Representative example of ChIP-seq data for PU.1 binding in K562 cells before and 
after 72-h SAHA treatment. The two sites highlighted increase in both DNase and PU.1 binding signal (n = 3 replicates). f The proportion of differen-
tial DHS sites overlapped by PU.1 ChIP-seq peaks. g Relationship between total PU.1 ChIP signal found in vehicle controls and SAHA-treated K562 at 
all PU.1 peaks. ChIP-seq signal is normalized by total number of mapped reads in each condition (Spearman’s correlation = 0.811)
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Surprisingly, depletion of PU.1 displayed no signifi-
cant differences in chromatin accessibility from con-
trol untreated K562 at an adjusted P value cutoff of 0.10 
(Fig. 5c; Additional file 8: Fig. S5B). These results indicate 
that normal PU.1 levels are not required for maintaining 
chromatin accessibility patterns in K562 cells, though we 
cannot rule out that residual low PU.1 protein levels are 
sufficient for the chromatin maintenance. Even more sur-
prisingly, we found no significant chromatin accessibility 
differences in PU.1-depleted versus control cells when 
treated with SAHA for 72  h (Fig.  5d; Additional file  8: 
Fig. S5C). We also detected no substantial differences in 
DNase signal in the subset of PU.1-bound DHS sites that 
open upon SAHA treatment (Fig. 5e, f; Additional file 8: 
Fig. S5D, E). This indicates that reduced levels of PU.1 do 
not prevent the altered chromatin accessibility patterns 
observed after SAHA treatment.
To determine whether PU.1 is required for the gene 
expression changes that occur with HDACi treatment, 
we performed RNA-seq on control and PU.1-depleted 
cells treated with or without SAHA. We identified just 
45 genes in untreated cells and 115 genes in SAHA-
treated cells significantly differential (FDR  <  0.05) with 
PU.1 knockdown (Additional file  9: Table S4). Of these, 
75.6 % (34/45) and 67.8 % (78/115) were also genes dif-
ferential as a result of SAHA treatment in our original 
RNA-seq analysis. This suggests that PU.1 knockdown 
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Fig. 4 PU.1 overexpression drives modest chromatin accessibility changes. a Western blot showing PU.1 overexpression (OE) produces a protein 
of the same size as endogenous PU.1. β-actin used as loading control (n = 2 replicates). b PU.1 overexpressing and vector control K562 mean 
DNase-seq signal found ±1 kb from DHS site center for all SAHA-opened DHS sites split into those that contain a PU.1 binding site (ChIP-seq peak) 
and those that do not. Light gray shading = SEM (n = 2 replicates). c PU.1-bound, SAHA-opened DHS sites exhibit greater mean fold-change of 
DNase-seq signal upon PU.1 overexpression than PU.1-bound sites that do not open with SAHA or SAHA-opened DHS sites without PU.1 binding. 
The cumulative fraction of DHS sites with each level of accessibility change is depicted. Mann–Whitney tests used to assess significance of the shift 
in distributions. d Two example DHS sites (shaded in gray boxes) found in an intron of TMEM51. The first (left) represents a SAHA-opened DHS site 
that does not have a PU.1 ChIP peak and exhibits no increase in accessibility following PU.1 overexpression. The second (right) represents a SAHA-
opened DHS site that does overlap PU.1 binding and exhibits a modest increase in accessibility following PU.1 overexpression
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K562. However, the distribution of changes in expression 
for genes differential upon SAHA treatment in vector 
control-transfected cells (999 genes at FDR  <  0.05) was 
remarkably similar to cells with PU.1 depleted (Addi-
tional file 10: Fig. S6A). Furthermore, a heatmap of these 
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Fig. 5 PU.1 depletion fails to block HDACi-induced chromatin accessibility changes. a Schematic of PU.1 shRNA knockdown strategy. K562 cells 
were transfected with a control vector, a vector containing an shRNA that targets PU.1, or mock transfected. Following 10 days of puromycin selec-
tion, stable knockdown cultures were obtained and immediately subjected to SAHA or vehicle control 72-h treatment followed by DNase-seq and 
RNA-seq profiling. b Western blot showing PU.1 levels before and after SAHA treatment for vector control-, shRNA 1-, or shRNA 2-transfected K562. 
β-actin was used as loading control (n = 2 replicates). c MA plot of fold-change in chromatin accessibility (DNase-seq) between vector control and 
PU.1 knockdown (shRNA 1) K562 over average signal found at each site. There are no significant DHS sites at P < 0.10 (n = 2 replicates). d MA plot 
of fold-change in chromatin accessibility between vector control and PU.1 knockdown (shRNA 1) K562 following 72-h SAHA treatment over aver-
age signal found at each site. There are no significant DHS sites at P < 0.10 (n = 2 replicates). e Boxplots of fold-change in chromatin accessibility 
between vehicle control and SAHA-treated K562 with vector control or shRNA knockdown of PU.1. Three sets of DHS sites are shown for compari-
son—PU.1-bound (overlaps ChIP-seq peak) sites that did not open in original SAHA treatment, PU.1-bound sites that open with original SAHA treat-
ment, and unbound sites that open with original SAHA treatment. f Representative DHS site located downstream of the SYF2 gene that opens with 
original 72-h SAHA treatment (DNase-seq) and contains a PU.1 ChIP-seq peak. The DHS site still opens in PU.1 shRNA knockdown cells
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between all SAHA-treated samples and all vehicle con-
trols (Additional file 10: Fig. S6B). These results indicate 
that PU.1 is not required for the vast majority of HDACi-
induced expression changes and further suggest other 
cofactors may be responsible for activation of opened 
enhancer elements.
Histone marks and transcription factor binding are 
predictive of HDACi response at PU.1‑bound DHS sites
To investigate what additional transcription factors or 
histone modifications might be required for HDACi-
induced chromatin opening and enhancer activation at 
PU.1-bound sites, we leveraged 112 transcription fac-
tor, 15 histone modification, and 18 chromatin-mod-
ifying factor ChIP-seq datasets available in untreated 
K562 cells from the Encyclopedia of DNA Elements 
(ENCODE) project [23]. We used a random forest clas-
sifier to identify factors or histone marks most informa-
tive for discriminating between PU.1-bound DHS sites 
that open with SAHA treatment and those that remain 
stable in accessibility. On ten separate classification runs 
with 75  % of input data randomly chosen to train and 
the remaining 25  % used for testing, we found the per-
formance was consistently better than chance (mean 
accuracy =  72.5  %) and the ranking of the top features 
was stable (Fig. 6a, b). The analysis identified H3K27me3 
as the top positive predictor, while GATA1 and TAL1 
appeared as top activating transcription factors predic-
tive of site opening (Fig. 6b).
Heatmaps of H3K27me3, GATA1, and TAL1 ChIP 
signal over the DHS sites used for classification show 
these three features are indeed enriched in PU.1-bound 
DHS sites that open with HDACi treatment (Fig. 6c–e). 
RNA-seq shows TAL1 and GATA1 significantly increase 
in expression following SAHA treatment (Additional 
file 3: Table S2) and the enriched binding of these hemat-
opoietic factors implicates them as regulators of the 
HDACi-induced enhancers. Interestingly, the presence 
of elevated H3K27me3 suggests PU.1-bound sites that 
open with HDACi may be poised in chromatin status for 
this response [24], while sites stable in accessibility may 












































































































































































Fig. 6 Chromatin features distinguish HDACi-opened from stable DHS sites bound by PU.1. a Performance of random forest classifier in distinguish-
ing PU.1-bound DHS sites that remain stable in accessibility from those that significantly open. Plot shows accuracy, specificity, and sensitivity for 
10 separate runs with 75 % of input data used for training and the remaining 25 % used for testing. b Ranking of top 15 features by Gini index. The 
same factor may appear more than once if data are available from multiple ENCODE centers. Broad Broad Institute, HAIB Hudson Alpha Institute 
for Biotechnology, UW University of Washington, SYDH Stanford, Yale, Davis, Harvard. Full results can be found in Additional file 12: Table S5. c–e 
Top positive predictors of PU.1-bound DHS site opening are shown as heatmaps of ChIP-seq signal present at each DHS site (DHS center ±5 kb for 
H3K27me3 and ±1.5 kb for TFs). Mean ChIP-seq signal in the same intervals plotted below
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by greater H3K36me3, H3K4me2, RNA polymerase 
II (Pol2), and H3K27ac signal (Fig.  6b) [25–27]. While 
not informative for distinguishing between opened and 
unchanged DHS sites, H3K4me1 signal also appears 
enriched in all PU.1-bound DHS sites ahead of HDACi 
treatment (Additional file 11: Fig. S7), consistent with our 
ChIP-qPCR data (Additional file 6: Fig. S3C).
Discussion
HDAC inhibitors have the ability to halt proliferation, 
induce cell death, or resensitize many cancers, but the 
pleiotropic effects of global hyperacetylation may limit 
their therapeutic potential. Isolating the processes under-
lying anticancer efficacy of HDACi from those that are 
harmful to normal cells is paramount to developing safer, 
more targeted therapies. We investigated the process of 
HDACi-induced cancer cell differentiation using K562 
cells that slow in growth and display markers of eryth-
roid lineage commitment with treatment [14, 28]. While 
histone acetylation levels increase genome wide follow-
ing HDACi treatment [6, 7], our data showed only about 
10  % of DHS sites change in K562 cells in response to 
treatment, with both opening and closing events. This 
implies that global hyperacetylation of histone tails is 
not sufficient to appreciably open local chromatin struc-
ture. These results are compatible with our RNA-seq 
data and previous expression studies identifying limited 
sets of differentially expressed genes following HDACi 
exposure [11, 12]. We postulate that the chromatin 
accessibility changes we observed were largely due to 
programmed enhancer element activation or repression 
as K562 cells undergo differentiation. The specificity of 
enhancer activity changes likely results from an exchange 
of specific transcription factors that either activate and 
increase accessibility or deactivate and decrease acces-
sibility. While it appears HDACi treatment is capable of 
gene repression, it may be the case that the DHS sites 
that close following HDACi treatment represent second-
ary effects of increased repressive transcription factor 
expression.
The reprogramming of K562 by HDACi-induced dif-
ferentiation may be very similar to the mechanism by 
which all-trans retinoic acid is used to treat acute pro-
myelocytic leukemia (APL). In APL, all-trans retinoic 
acid induces differentiation of leukemic promyelocytes 
into mature granulocytes [13]. Chromosomal rearrange-
ments in APL most commonly fuse the retinoic acid 
receptor-alpha (RARA) gene to the promyelocytic leuke-
mia (PML) gene, generating a hybrid protein that binds to 
genes involved in normal granulocyte differentiation and 
recruits the nuclear corepressor (NCoR) complex [29]. 
NCoR represses gene expression by recruiting HDACs, 
and all-trans retinoic acid alleviates this repression by 
effectively displacing NCoR. Indeed, this connection 
between HDAC-mediated gene repression in APL and 
the mechanism of HDACi treatments has been sug-
gested before [30]. Our evidence of specific chromatin 
and gene expression changes driving K562 differentiation 
in the presence of HDACi support the idea that similar 
complexes may repress tumor suppressor genes, and this 
repression is alleviated after treatment.
Our motif enrichment analysis and expression data 
implicated the pioneer factor PU.1 in the HDACi-
induced opening of DHS sites. ChIP-seq for PU.1 before 
and after treatment demonstrated that this transcription 
factor binds many of the opened DHS sites and increases 
binding following HDACi treatment. PU.1 is known to be 
critical for enhancer activation and chromatin changes 
in B cell and macrophage differentiation [16, 17]. How-
ever, we found evidence that PU.1 is not a major driver of 
HDACi enhancer activation in K562 cells. Forced overex-
pression of PU.1 only produced modest chromatin acces-
sibility increases at a subset of bound loci, and reduction 
of PU.1 levels by shRNA knockdown did not prevent 
the chromatin accessibility increases or gene expres-
sion changes with HDACi treatment. However, we can-
not rule out PU.1 may be still acting as a pioneer factor 
earlier during the development of the K562 epigenome 
and more important for poising future enhancer sites. It 
is also possible that low residual PU.1 levels are enough 
to initiate the process of chromatin remodeling and that 
increased binding at opened DHS sites is not important 
for this process. Creating a PU.1 null cell line may help 
address this possibility. Lastly, it may be the case that 
other factors, including ETS family proteins, are func-
tionally redundant in the chromatin remodeling process 
and capable of assuming PU.1’s enhancer activation role 
in K562.
Using a random forest classifier, we identified the his-
tone mark H3K27me3 as the strongest positive predic-
tor for PU.1-bound DHS sites to respond to HDACi 
treatment with chromatin accessibility increases. Addi-
tionally, we found that the chromobox proteins CBX2 
and CBX8, which are components of Polycomb repres-
sor complexes that maintain H3K27me3 marks [31], are 
enriched at the responsive DHS sites (Fig. 6b; Additional 
file 11: Fig. S7B, C). The dual presence of H3K27me3 and 
H3K4me3 has been described as “bivalent domains” with 
competing activating and repressive modifications that 
together mark poised promoter regions during devel-
opment [24]. As cells differentiate, they can potentially 
activate or repress marked genes by changing histone 
modifications and chromatin accessibility status. Simi-
larly, H3K4me1 in combination with H3K27me3 marks 
poised distal enhancer elements [32]. The presence of the 
H3K4me1 and H3K27me3 marks, together with the low 
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levels of PU.1 binding prior to HDACi treatment, sug-
gests the HDACi-opened DHS sites we observed might 
be initially poised for enhancer activity and a chroma-
tin remodeling response in K562 cells. In this model, 
once de-repressed by removal of HDAC function, these 
enhancers become activated and drive gene expression 
patterns that coordinate the erythroid differentiation 
process. The PU.1-bound DHS sites that do not signifi-
cantly increase accessibility with HDACi treatment likely 
include more sites that are already active enhancers, as 
evidenced by enriched H3K36me3, Pol2, H3K4me2, and 
H3K27ac signal (Fig. 6b) [25–27].
We also found a moderate enrichment of GATA1 and 
TAL1 binding at opening PU.1-bound DHS sites. The 
GATA family motif was enriched in our sets of HDACi-
opened and HDACi-closed DHS sites in general (Addi-
tional file  4: Fig. S2). PU.1 and GATA1 are capable of 
inhibiting each other’s function by protein–protein inter-
actions that block DNA binding [33, 34], but it is unclear 
how that mechanism may be involved in this process. 
TAL1 has been shown to be required for chromatin loop-
ing between the β-globin locus control region and the 
γ-globin gene to enhance its expression in K562 cells, 
demonstrating a role it plays in this system to establish 
functional enhancers [35]. The extent to which PU.1, 
GATA1, and TAL1 cooperatively interact to control 
enhancer activation following HDACi treatment is cur-
rently unknown and will be the target of future studies. 
As the role of lineage-committing transcription factors 
and chromatin changes in induced cancer cell differentia-
tion are better defined, strategies can be further refined 
to inform more targeted cancer treatments.
Conclusions
We found that despite widespread hyperacetylation, 
HDACi cause site-specific chromatin remodeling in the 
genome of K562 cells with roughly equal numbers of 
DHS sites gaining or losing accessibility. Opening DHS 
sites often reflect gain of enhancer activity at sites marked 
by PU.1 binding that increases with HDACi treatment. 
PU.1-bound DHS sites with the largest accessibility gains 
appear to be epigenetically poised by a combination of 
repressive H3K27me3 and activating H3K4me1 histone 
marks. Together, these results help explain the ability of 
HDACi to drive differentiation of K562 cells at suble-
thal concentrations by activating and deactivating par-
ticular enhancer elements to regulate gene expression 
in a pre-programmed manner. We postulate a similar 
directed differentiation process underlies HDACi efficacy 
against various leukemias and contributes to the ability of 
HDACi to sensitive cancer cells to other drugs in combi-
nation therapies.
Methods
K562 cell culture and HDACi treatments
K562 cells were obtained from ATCC (CCL-243) and 
maintained in 1× RPMI1640 media supplemented with 
10 % FBS and 1× antibiotic–antimycotic (Life Technolo-
gies). Initial titrations of the HDACi NaBut and SAHA 
(Sigma-Aldrich) were performed to determine the maxi-
mum concentration with which <10 % of cells are killed 
at 72 h by Trypan blue staining. Addition of NaBut dis-
solved in 1× PBS to 0.5  mM or SAHA dissolved in 
DMSO to 1 μM final concentration versus an equal vol-
ume of vehicle was used for all 72-h exposures presented 
with the exception of 2  mM NaBut presented in Addi-
tional file 1: Fig. S1. Additionally, 1 mM NaBut was used 
for the shorter 24-h treatments with luciferase reporter 
constructs.
DNase‑seq
15–50 million K562 nuclei were spun down, washed 
twice with 1× PBS, divided, and digested with a range 
of recombinant DNase I enzyme (Roche) concentrations 
(between 0.12 and 12 U) for 16 min at 37  °C in 120 μL 
1× DNase buffer. DNase-seq libraries were constructed 
as previously described [36]. Briefly, each set of diges-
tions was checked by pulsed-field gel electrophoresis, 
and material was pooled in equimolar amounts follow-
ing blunt-ending reactions from three different DNase 
concentrations to match extent of digestion (0.36, 1.2, 
and 3.6  U used in all experiments). Following ligation 
to adapters, MmeI digestion, streptavidin bead-based 
enrichment, and 14 cycles of linker-mediated PCR, 
each library was sequenced for 50 cycles on the Illumina 
HiSeq2000 platform, with the exception of the first repli-
cate of NaBut treatments, which were sequenced for 36 
cycles on a GAIIx machine. Three replicates (beginning 
with a new K562 frozen stock) were processed per condi-
tion with HDACi-treated and corresponding vehicle con-
trol samples co-processed throughout each replicate.
DNase-seq reads were trimmed to the first 20 bp (fixed 
insert length generated by MmeI digest) and aligned 
to the UCSC hg19 reference genome using Bowtie [37] 
allowing up to 1 mismatch and requiring unique align-
ments. Potential PCR artifacts were filtered from align-
ment by removing reads where greater than 70 % map to 
a single bp within a 31-bp window [38]. Reads mapping 
to ENCODE blacklisted regions [23], mitochondria, and 
chrY were removed from alignment. MACS2 [39] was 
used to call peaks (FDR  <  0.05) and generate genome 
coverage files by artificially extending DNase reads to 
200 bp in length and centering on 5′ read ends. bigWig 
files for browser images were normalized to millions of 
reads aligned per sample.
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For differential signal tests, raw read counts were tab-
ulated for the union of all peak calls across replicates as 
input for DESeq2 [18]. Principle components analysis 
and clustering by Euclidean distance were executed using 
DESeq2 following regularized log transformation of nor-
malized read counts of DNase signal found in all peaks. 
DHS sites were associated with the single nearest hg19 
reference gene for expression level comparisons. DHS 
sites mapping within 2 kb of an annotated TSS were con-
sidered promoter-located, and all other DHS sites were 
considered distal. Enriched motifs in differential DHS 
sites were identified using MEME-ChIP [40] with align-
ments to JASPAR and UniPROBE databases.
Chromatin immunoprecipitation
ChIP was performed essentially as previously described 
[41]. Briefly, 20 million K562 cells per ChIP were cross-
linked with 1 % formaldehyde for 10 min, quenched with 
0.125 M glycine, and lysed. DNA was sonicated by 45 min 
with 30-s on/off cycles on a Bioruptor (Diagenode) in 
RIPA buffer. An aliquot of sonicated material was reserved 
for agarose gel sizing and for an input chromatin control 
sample with each treatment. After resuspending chro-
matin in 1 % Triton X-100, 2 mM EDTA, 20 mM TrisCl, 
150 mM NaCl buffer, and pre-clearing material with Pro-
tein A Dynabeads (Life Technologies) for 2 h at 4 °C, 6 μg 
of the following antibodies was incubated with the soni-
cated chromatin overnight at 4  °C: rabbit anti-PU.1 Santa 
Cruz Biotech sc-22,805 and rabbit anti-H3K4me1 Abcam 
ab8895. Protein A beads were bound to antibody for 3  h 
at 4  °C and then washed five times with LiCl wash buffer 
(500  mM LiCl, 100  mM TrisCl, 1  % NP40, 1  % sodium 
deoxycholate) and once with 1× TE. Cross-linking was 
reversed with overnight 65 °C incubation in 1 % SDS and 
0.1 M sodium bicarbonate buffer, and DNA was eluted with 
a PCR cleanup kit (Qiagen). Following TruSeq adapter liga-
tions, DNA fragments were separated from free adapters 
by AmpureXL bead size selection steps, and PCR amplifi-
cation was performed for 18 cycles. ChIP-seq libraries were 
sequenced on the Illumina HiSeq2000 machine with 50-bp 
SE reads. Three replicates (beginning with a new K562 
frozen stock) were processed per condition with HDACi-
treated and corresponding vehicle control samples co-pro-
cessed throughout each replicate to mitigate batch effects.
ChIP-seq reads were aligned to the hg19 reference 
genome using Bowtie [37] allowing up to 1 mismatch 
and requiring unique alignments. Putative PCR arti-
facts and reads mapping to blacklisted regions, mito-
chondrial, or chrY sequences were removed exactly 
as with DNase-seq alignments. Peak calls were gener-
ated by MACS2 [39] with default settings at FDR < 0.05 
over K562 input background samples with match-
ing vehicle or HDACi treatment where appropriate. 
Genome browser visualizations were normalized by 
total mapped reads in each sample. Genomic regions 
tested for enrichment by qPCR were amplified with 
the following primers: S1, F: ACTTCCCCTTTCCCT 
TGCT, R: GGGCTGGGAGGACTACTGTG; S2, F: 
GCCTTGGGCAGATGTACAAA, R: TTCCACTTCCTC 
TTTCTGTGC; S3, F: ACCAGAGGTCCCTGGAG 
TG, R: CTGGGAGGACAGCTGCTAAG; S4, F: TCAAG 
TCGTGGTTTGGATGA, R: GGGGTACCTCTCACC 
ACTCA; S5, F: GATCTTGGGGGTGGCTTG, R: AA 
GTGAGAAGGGGCTGTTGT; S6, F: GACTGGGGGAA 
GGACCTCT, R: CCAGCACGAAGCTGACTGAT; C1, 
F: TCTCTGGGGAGATGGATTACA, R: CGTGAATC 
CTTTATTCTTGGAA; C2, F: CCAATAACAGAAG 
CATTAAAATTCA, R: TTCAAGCACAGGCATAC 
AGG.
RNA‑seq
RNA was isolated from 5 to 10 million K562 cells with 
an RNeasy Mini kit (Qiagen) with on-column DNase 
digestion. Two microgram of total RNA was used for 
TruSeq library preparation with polyA selection. Librar-
ies for initial NaBut and SAHA versus vehicle control 
experiments were subjected to 50-bp paired-end Illumina 
HiSeq2000 sequencing to an average depth of 40.2 mil-
lion read pairs. Libraries for SAHA versus vehicle control 
with PU.1 depleted by shRNA were sequenced as 50-bp 
SE on Illumina HiSeq with average depth of 36.4 million 
reads. Following quality-score-based trimming, reads 
were aligned to hg19 UCSC genes with Tophat v2.0.12 
[42] allowing up to 2 mismatches. FPKM estimates for 
individual samples were obtained with Cufflinks v2.2.1, 
and differential genes across conditions were identified 
with Cuffdiff v2.2.1 [43]. Three (for NaBut treatment) 
or two (for SAHA treatments) independent replicates 
(beginning with new K562 frozen stock) were processed 
with HDACi-treated and corresponding vehicle control 
samples in parallel throughout.
Classification of opened versus stable sites
In order to identify transcription factors and epigenetic 
marks associated with increased accessibility of DHS 
sites bound by PU.1, we implemented a random forest 
classifier to distinguish sites that open from those that 
do not significantly change accessibility following HDACi 
treatment. We used all ChIP-seq data available through 
ENCODE (genome assembly hg19) for the untreated 
K562 cell line (“treatment =  None”) with the exception 
of experiments labeled with “revoked” status. A total of 
112 transcription factor, 15 histone modification, and 18 
chromatin-modifying factor ChIP-seq alignments were 
downloaded and processed with MACS2 (v2.10) [39] 
to generate fragment pileup scores (bedGraph format) 
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over input control. Before classification, we removed all 
DHS sites localizing to known gene promoters or exons 
(based on UCSC hg19 known genes). Next, to control 
for the DNase-seq and PU.1-binding signal in the sets of 
opened versus stable sites used for classification, for each 
opened DHS site we randomly selected a stable DHS site 
with close to equal baseline DNase-seq and PU.1 ChIP-
seq signal in untreated K562 cells. DHS center ±200 bp 
was used for DNase signal, and DHS center ±150  bp 
was used for PU.1 ChIP signal matching. This resulted 
in ~930 opened and stable sites used for classification. 
For each selected DHS site, transcription factor features 
were computed as the maximum ChIP-seq pileup signal 
over 200-bp windows with 100-bp overlap in the DHS 
site (defined as DHS site center ±300 bp). For chromatin-
modifying factors, we used a larger region of DHS center 
±700 bp. For histone modifications, we summed the total 
ChIP-seq signal in the DHS center ±700 bp. The random 
forest classifier was run through R package “randomFor-
est” with “mtry” set to 10 and “ntree” set to 500. 75  % 
of the input data were used to train the model and 25 % 
reserved for testing. The random splitting of training and 
testing samples followed by classification was repeated 10 
times to assess the stability of the top features and clas-
sification accuracy. The importance score of each fea-
ture was computed as the Gini index value and the mean 
decrease in accuracy when its class labels are randomly 
permuted. Heatmap and summary plots were generated 
using deepTools software [44].
Luciferase assays
~800  bp of each DHS site was cloned upstream of the 
minimal promoter in a pGL4.23 luciferase reporter vector 
(Promega) using amplicons generated with the following 
primers (hg19): chr1:228639823–228640570, F: GAT-
GACTGGGGGAAGTCTCA, R: GACAGCAGGTGT 
CTGGTGAA; chr11: 76847652–76848380, F: AGTTAA 
CCATGGCTGGCACT, R: GCAACGAAAAAGACGG 
TGAT; chr19: 8641896–8642579, F: TTGTCCCTGCAGA 
CTCTGTG, R: CTGAATCGCCCTGAAAAGAG; chr5: 
95168365–95169111, F: CCATTTCTGCCTCCCTCATA, 
R: GCGCTTTCCGACTACTCATC; chr6: 41690943–416 
91723, F: CCTTCTTCCCCATTCTTTCC, R: AGGAAGA 
TGGTGAGCTGTGG; chr19: 6778173–6778776, F: CCT 
GACCTTAAGTGACCCACA, R: CAGGCAAAATT 
GGGTTTTGT; chr7: 100839167–100839788, F: AGTG 
GGTGGAGGTCTCAGTG, R: TGAATGACCCTGGG 
AGGTAG; chr1: 35384552–35385452, F: TCCTCGTGTC 
TGCTGTGATG, R: TTTTTGGTCTGGCAGTAGGG; 
chr9: 131900863–131902480, F: ATCCCTCCTCAGTCC 
CTTTC, R: AGGGGAATCGTGTGAGTCAG. Inserts 
were verified by Sanger sequencing. K562 cells were 
transferred to antibiotic-free media 24-h preceding 
transfection. 15,000 K562 cells were added per well to 
96-well plates and transfected with the pGL4.23 con-
struct and pGL4.73 Renilla control plasmid using 
Lipofectamine LTX with Plus reagent (Thermo Fisher 
Scientific) following manufacturer’s protocol. 24  h after 
transfection, 1 mM NaBut, 1 μM SAHA, or an equal vol-
ume of 1× PBS or DMSO vehicle was added to each well. 
24  h after HDACi addition, cells were simultaneously 
lysed and exposed to substrate following manufacturer’s 
instructions for the dual-luciferase reporter system (Pro-
mega). Plate emissions were read on a VICTOR2 multi-
label counter plate reader (Perkin Elmer). Measurements 
were performed in technical replicates of six wells, nor-
malized per well by Renilla output, and normalized per 
plate by average empty pGL4.23 signal. Each construct 
was tested with at least two separate sets of transfec-
tions on different days. The positive control region (chr9: 
131900863–131902480) overlaps an alternative promoter 
of PPP2R4 that we observed exhibits strong enhancer 
activity with luciferase reporters in K562 cells, but does 
not significantly open with HDACi treatment.
PU.1 shRNA knockdown
We purchased shRNAs targeting human PU.1 mRNA 
that were cloned in the lentiviral vector pLKO.1 (Sigma-
Aldrich) and obtained a non-hairpin control pLKO.1 
(Addgene plasmid #10879 from David Root). Five shR-
NAs targeting PU.1 were tested for knockdown effi-
ciency, and the two most effective, TRCN0000426240 
and TRCN0000417534, were selected for subsequent use. 
shRNA vectors were introduced by transfection of 10 
million K562 cells with Lipofectamine LTX with Plus rea-
gent (Thermo Fisher Scientific) following manufacturer’s 
protocol. 24 h after transfection, puromycin (Gibco) was 
added to media to 2 μg/mL for selection over 10–12 days. 
Puromycin was reduced to 1 μg/mL during 72-h SAHA 
treatments. Knockdown efficiency was evaluated by 
qPCR or western blot on days cells were subjected to 
DNase-seq.
PU.1 overexpression
PU.1 cDNA was obtained by reverse transcription from 
K562 total RNA extracts and amplification with following 
primers (IDT): F: TGACGGATCC GCCGCCACCATG 
TTACAGGCGTGCAAAATG, R: TGACGCGGCCG 
CTCAGTGGGGCGGGTGG that amplify from start 
to stop codons of PU.1 cDNA with addition of a Kozak 
sequence, and BamHI and NotI recognition sites. BamHI 
and NotI double digest (NEB) was used to clone the 
amplified cDNA into the pTargeT mammalian expres-
sion vector (Promega), and the insert was verified with 
Sanger sequencing. The PU.1 overexpression construct 
or empty pTarget was introduced to 0.5 million K562 
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cells by transfection with Lipofectamine LTX with Plus 
reagent (Thermo Fisher Scientific) following manufac-
turer’s protocol. 24 h following transfection, media were 
supplemented with 400  μg/mL G418 disulfate (Sigma-
Aldrich) for 12–14 days of selection. Following selection, 
G418 concentration was reduced to 250 μg/mL and cells 
were expanded for 3–4 days. Overexpression was verified 
by qPCR or western blot on days cells were subjected to 
DNase-seq.
Quantitative RT‑PCR
1–2  μg of total RNA was used for reverse transcription 
with oligo dT primers and Superscript II (Invitrogen). 
Quantitative SYBR green PCR was performed on an 
ABI 7500 real-time PCR machine (Applied Biosystems) 
using the following primers (IDT): PU.1, F: TGTTAC 
AGGCGTGCAAAATG, R: TCATAGGGCACCAGG 
TCTTC; β-actin, F: GCCGGGACCTGACTGACTAC, R: 
TTCTCCTTAATGTCACGCACGAT; CDKN1A, F: GAC 
TCTCAGGGTCGAAAACG, R: GGATTAGGGCTTCC 
TCTTGG. Each sample was measured in technical tripli-
cate and normalized to β-actin.
Western blots
5–10 million K562 cells were lysed in RIPA buffer and 
spun down at 10,000 RPM for 15  min to remove cell 
debris. Samples were disrupted by brief sonication, a 
BCA assay (Pierce) was used to measure protein con-
centrations, and 10  μg of each lysate was loaded per 
lane for SDS-PAGE. Gels were transferred to nitrocel-
lulose for blotting. Primary antibodies used were rab-
bit anti-PU.1 Abcam ab76543 and mouse anti-β-actin 
Santa Cruz Biotech sc-81178. Bands were visualized 
by supplying substrate for the following HRP-conju-
gated secondary antibodies: goat anti-rabbit Pierce 
#31462 and goat anti-mouse Santa Cruz Biotech 
sc-2005.
Data access
All sequencing data presented here (with the exception 
of ENCODE ChIP-seq datasets referenced above) have 
been deposited as GEO entry GSE74999.
Additional files
Additional file 1: Table S1. DESeq2 output for differential accessibility 
(DNase-seq) following 72-h NaBut or SAHA treatment of K562 cells.
Additional file 2: Figure S1. Chromatin accessibility changes induced 
by NaBut or SAHA in K562 cells exhibit high concordance. Mean DNase-
seq signal found +/− 2 kb from center of each DHS site called significant 
in DESeq analysis for NaBut opened (a), NaBut closed (b), SAHA opened 
(c), and SAHA closed (d). DMSO is vehicle control for SAHA treatments and 
PBS is vehicle control for NaBut treatments. Note the directional concord-
ance between NaBut and SAHA treatments. Gray shading indicates SEM 
between replicates (n = 3 replicates). RPM = Reads per million mapped. 
(e) MA plot of fold-change in chromatin accessibility (DNase-seq signal) 
over average signal found at each site following 72-hour treatment of 
K562 with 2 mM NaBut. Red marks DHS sites with significantly changed 
chromatin accessibility (FDR < 0.05, n = 2 replicates). (f ) Heatmap of 
Euclidean distance between regularized log-transformed DNase-seq data 
for vehicle control K562 (DMSO or PBS) and HDACi-treated K562 (0.5 mM 
NaBut, 2 mM NaBut, or 1 uM SAHA). Note the agreement between repli-
cates and the clustering of HDACi-treated vs. untreated samples.
Additional file 3: Table S2. Cuffdiff output for differentially expressed 
(RNA-seq) genes following 72-hour NaBut or SAHA treatment of K562 
cells.
Additional file 4: Figure S2. Motif enrichment in differential DHS sites. 
The top four enriched motifs (MEME-ChIP results) found in opened or 
closed DHS sites are listed with corresponding position weight matrix, 
expected (E) value, and top factor match found in the JASPAR or Uni-
PROBE databases.
Additional file 5: Table S3. RNA-seq expression data for ETS family 
transcription factors detected in K562 cells.
Additional file 6: Figure S3. PU.1 and H3K4me1 immunoprecipitation. 
ChIP-qPCR for six DHS sites that open in K562 cells following HDACi treat-
ment and a control site that does not change accessibility. PU.1 enrich-
ment before and after 72-hour (a) SAHA or (b) NaBut treatment and (c) 
H3K4me1 enrichment before and after SAHA treatment for each site was 
measured. Enrichment is normalized to that measured in respective input 
control samples. Error bars are SEM (n = 3 replicates).
Additional file 7: Figure S4. PU.1 overexpression-driven chromatin 
accessibility changes are not linked to initial PU.1 ChIP peak strength. (a) 
PU.1 expression levels measured by RNA-seq FPKM before and after HDACi 
treatments. Error bars are SEM (n = 2 replicates for SAHA, 3 replicates for 
NaBut). (b) Fold-change in expression level of PU.1 measured by qPCR 
following PU.1 overexpression construct transfection and selection. 
Expression normalized to β-actin. Error bars are SEM (n = 3 replicates). 
(c) Distribution of PU.1 ChIP-seq signal found within 1 kb of DHS site 
center for SAHA-opened DHS sites that overlap PU.1 ChIP peaks and 
SAHA-unchanged (stable) DHS sites that overlap PU.1 ChIP peaks. Curves 
with lower mean are PU.1 signal for vehicle treated K562, and curves with 
greater mean are PU.1 signal for SAHA-treated K562. Signal is average of 
three replicates.
Additional file 8: Figure S5. PU.1 knockdown fails to block most HDACi-
induced chromatin accessibility changes in K562. (a) PU.1 expression levels 
after 72-hour SAHA exposure for vector control-, shRNA 1-, and shRNA 
2-transfected K562 cells measured by qPCR. Expression normalized to 
β-actin. Error bars are SEM (n = 3 replicates). (b) MA plot of fold-change 
in chromatin accessibility (DNase-seq) between vector control and PU.1 
knockdown (shRNA 2) K562 over average signal found at each site. There 
are no significant DHS sites at P < 0.10 (n = 2 replicates). (c) MA plot of 
fold-change in chromatin accessibility between vector control and PU.1 
knockdown (shRNA 2) K562 following 72-hour SAHA treatment over 
average signal found at each site. There are no significant DHS sites at 
P < 0.10 (n = 2 replicates). (d) Mean DNase-seq signal for vector control 
or PU.1 knockdown K562 in original SAHA-opened DHS sites that overlap 
a PU.1 ChIP-seq peak. RPM = reads per million mapped. (n = 2 replicates 
for vector control, n = 4 replicates for shRNA 1 and 2 combined). (e) 
Mean DNase-seq signal for vector control or PU.1 knockdown K562 in 
original SAHA-opened DHS sites that do not contain a PU.1 binding site. 
RPM = reads per million mapped. (n = 2 replicates for vector control, 
n = 4 replicates for shRNA 1 and 2 combined).
Additional file 9: Table S4. Cuffdiff output for differentially expressed 
(RNA-seq) genes following PU.1 shRNA knockdown in K562 cells.
Additional file 10: Figure S6. PU.1 depletion fails to block HDACi-
induced gene expression changes in K562. (a) Boxplots of fold-change in 
RNA-seq expression for SAHA treatment of vector control-, shRNA 1-, or 
shRNA 2-transfected cells (n = 2 replicates) for genes that either increase 
or decrease significantly in vector control K562 (FDR < 0.05). (b) Heatmap 
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